BTIG Research Begins Coverage on CeriBell (NASDAQ:CBLL)

Equities research analysts at BTIG Research started coverage on shares of CeriBell (NASDAQ:CBLL - Get Free Report) in a note issued to investors on Tuesday,Briefing.com Automated Import reports. The firm set a "buy" rating and a $30.00 price target on the stock. BTIG Research's price target points to a potential upside of 62.25% from the company's previous close.

Other research analysts have also issued reports about the company. LADENBURG THALM/SH SH assumed coverage on CeriBell in a report on Friday, April 4th. They set a "buy" rating and a $32.00 price target on the stock. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $33.00 price target on shares of CeriBell in a research note on Wednesday, February 26th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $32.14.

CeriBell Price Performance

CeriBell stock opened at $18.49 on Tuesday. CeriBell has a 1 year low of $10.01 and a 1 year high of $32.75. The firm's 50-day moving average is $16.74 and its 200-day moving average is $20.55. The company has a debt-to-equity ratio of 0.11, a quick ratio of 16.81 and a current ratio of 17.36.

CeriBell (NASDAQ:CBLL - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.36) EPS for the quarter, beating analysts' consensus estimates of ($0.43) by $0.07. The company had revenue of $20.49 million during the quarter, compared to analyst estimates of $19.30 million. As a group, research analysts forecast that CeriBell will post -2.46 earnings per share for the current year.

Insider Buying and Selling

In other CeriBell news, Director Rebecca B. Robertson sold 20,000 shares of the stock in a transaction on Monday, June 16th. The shares were sold at an average price of $17.14, for a total value of $342,800.00. Following the completion of the sale, the director now directly owns 28,675 shares of the company's stock, valued at $491,489.50. This represents a 41.09% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Xingjuan Chao sold 25,000 shares of the company's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $17.00, for a total transaction of $425,000.00. Following the transaction, the chief executive officer now directly owns 776,022 shares of the company's stock, valued at $13,192,374. This represents a 3.12% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 113,333 shares of company stock worth $1,895,195. Insiders own 20.10% of the company's stock.

Institutional Investors Weigh In On CeriBell

Institutional investors have recently bought and sold shares of the business. FMR LLC bought a new stake in CeriBell in the fourth quarter valued at about $128,120,000. TPG GP A LLC acquired a new position in CeriBell during the 4th quarter worth $102,677,000. Red Tree Management LLC acquired a new stake in shares of CeriBell in the 4th quarter valued at $57,083,000. Yu Fan acquired a new position in shares of CeriBell during the fourth quarter valued at $31,631,000. Finally, ABG WTT Global Life Science Capital Partners GP Ltd bought a new position in CeriBell in the fourth quarter valued at about $28,160,000.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.